B
Pfizer Inc.
PFE
NYSE
$50.66 -$1.22-2.35% Volume16,458,770 06/28/2022 4:00PM Eastern Quotes delayed
Recommendation
Prev Close
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
B
Buy 1/7/2022Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2022 due to an increase in the total return index and volatility index.
B
Buy 12/21/2021Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 12/21/2021 due to a decline in the valuation index and dividend index.
B
Buy 11/15/2021Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 11/15/2021 due to a major increase in the valuation index, total return index and growth index. Earnings per share increased from $0.9842 to $1.4184, EBIT increased 41.92% from $6.23B to $8.84B, and total revenue increased 26.96% from $18.98B to $24.09B.
B
Buy 8/16/2021Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 8/16/2021 due to an increase in the volatility index, total return index and solvency index.
C
Hold 7/9/2021Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/9/2021 due to an increase in the volatility index, total return index and valuation index.
C
Hold 6/24/2021Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 6/24/2021 due to a decline in the valuation index.
C
Hold 6/7/2021Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 6/7/2021 due to a large increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.1054 to $0.8616, EBIT increased 215.07% from $1.63B to $5.14B, and total revenue increased 24.8% from $11.68B to $14.58B.
C
Hold 11/12/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/12/2020 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 41.21% from $3.56B to $2.09B, earnings per share declined from $0.61 to $0.39, and net income declined 35.96% from $3.43B to $2.19B.
C
Hold 9/8/2020Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 9/8/2020 due to an increase in the volatility index and valuation index.
C
Hold 8/7/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 8/7/2020 due to a noticeable decline in the valuation index, solvency index and total return index. Debt to equity increased from 0.8 to 0.99.
C
Hold 7/23/2020Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/23/2020 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0625 to $0.61, EBIT increased 92% from $2.29B to $4.39B, and the quick ratio increased from 0.59 to 0.7.
C
Hold 3/20/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/20/2020 due to a decline in the volatility index.
C
Hold 3/19/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 3/19/2020 due to a decline in the volatility index, total return index and solvency index.
B
Buy 3/4/2020Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 3/4/2020 due to a noticeable increase in the valuation index, volatility index and efficiency index.
C
Hold 2/24/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/24/2020 due to a decline in the total return index and volatility index.
B
Buy 1/7/2020Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 1/7/2020 due to an increase in the valuation index and total return index.
C
Hold 9/25/2019Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/25/2019 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.85 to 0.83, and debt to equity increased from 0.78 to 0.79.
B
Buy 7/30/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 7/30/2019 due to a large decline in the volatility index, growth index and solvency index. Operating cash flow declined 64.16% from $4.74B to $1.7B, debt to equity increased from 0.66 to 0.79, and the quick ratio declined from 0.95 to 0.85.
B
Buy 3/4/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 3/4/2019 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.6918 to -$0.0679, debt to equity increased from 0.58 to 0.66, and EBIT declined 12.18% from $3.93B to $3.45B.
B
Buy 2/21/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B+ from A- on 2/21/2019 due to a decline in the total return index and volatility index.
A
Buy 1/11/2019Upgraded
Pfizer Inc. (PFE) was upgraded to A- from B+ on 1/11/2019 due to an increase in the total return index.
B
Buy 12/27/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B+ from A- on 12/27/2018 due to a decline in the total return index, growth index and dividend index. EBIT declined 5.28% from $4.32B to $4.09B, and total revenue declined 1.25% from $13.47B to $13.3B.
A
Buy 9/10/2018Upgraded
Pfizer Inc. (PFE) was upgraded to A- from B on 9/10/2018 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 94% from $1.98B to $3.85B, earnings per share increased from $0.5898 to $0.65, and total revenue increased 4.34% from $12.91B to $13.47B.
B
Buy 5/21/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 5/21/2018 due to an increase in the volatility index, valuation index and efficiency index.
B
Buy 5/8/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 5/8/2018 due to a decline in the volatility index and total return index.
B
Buy 4/12/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 4/12/2018 due to an increase in the volatility index and valuation index.
B
Buy 3/28/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 3/28/2018 due to a noticeable decline in the volatility index, efficiency index and dividend index.
B
Buy 2/20/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 2/20/2018 due to an increase in the volatility index, valuation index and dividend index.
B
Buy 2/5/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 2/5/2018 due to a noticeable decline in the volatility index and dividend index.
B
Buy 10/10/2017Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 10/10/2017 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 104.66% from $1.59B to $3.25B, total revenue increased 0.92% from $12.78B to $12.9B, and earnings per share increased from $0.51 to $0.5103.
B
Buy 6/5/2017Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/5/2017 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1228 to $0.51, and EBIT increased 62.76% from $2.55B to $4.16B.
C
Hold 4/24/2017Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 4/24/2017 due to an increase in the valuation index, growth index and efficiency index. Total revenue increased 4.46% from $13.05B to $13.63B.
C
Hold 11/17/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/17/2016 due to a decline in the volatility index and valuation index.
C
Hold 11/14/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 11/14/2016 due to a decline in the valuation index, volatility index and efficiency index. Net income declined 34.62% from $2.02B to $1.32B.
B
Buy 11/9/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C on 11/9/2016 due to a noticeable increase in the volatility index and valuation index.
C
Hold 11/8/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from B- on 11/8/2016 due to a noticeable decline in the volatility index and total return index.
B
Buy 11/1/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 11/1/2016 due to an increase in the valuation index and dividend index.
C
Hold 9/14/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/14/2016 due to a noticeable decline in the total return index.
B
Buy 8/12/2016Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 8/12/2016 due to a noticeable decline in the growth index, valuation index and efficiency index. Net income declined 33.06% from $3.02B to $2.02B, earnings per share declined from $0.49 to $0.3302, and EBIT declined 6.37% from $4.14B to $3.88B.
B
Buy 8/10/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 8/10/2016 due to a major increase in the total return index and volatility index.
B
Buy 6/8/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/8/2016 due to a noticeable increase in the volatility index, solvency index and total return index.
C
Hold 5/18/2016Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 5/18/2016 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.0305 to $0.49, and EBIT increased 83.28% from $2.26B to $4.14B.
C
Hold 3/4/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/4/2016 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.3413 to -$0.0305, and EBIT declined 42.86% from $3.96B to $2.26B.
C
Hold 2/3/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/3/2016 due to a decline in the volatility index, total return index and solvency index.
B
Buy 11/6/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 11/6/2015 due to a substantial decline in the volatility index, total return index and valuation index.
B
Buy 7/15/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 7/15/2015 due to a noticeable decline in the volatility index and total return index.
B
Buy 5/8/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B+ from B on 5/8/2015 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1925 to $0.3808.
B
Buy 2/27/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 2/27/2015 due to a decline in the valuation index, solvency index and dividend index. Debt to equity increased from 0.48 to 0.51.
B
Buy 2/10/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B+ from B on 2/10/2015 due to a large increase in the volatility index and total return index.
B
Buy 1/7/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2015 due to an increase in the volatility index, total return index and valuation index.
B
Buy 12/23/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 12/23/2014 due to a decline in the volatility index, total return index and valuation index.
B
Buy 12/8/2014Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 12/8/2014 due to an increase in the volatility index.
B
Buy 11/7/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 11/7/2014 due to a substantial decline in the valuation index, growth index and volatility index. Earnings per share declined from $0.4519 to $0.4195, EBIT declined 4.85% from $4.27B to $4.06B, and total revenue declined 3.23% from $12.77B to $12.36B.
B
Buy 8/6/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B from A- on 8/6/2014 due to a large decline in the volatility index and total return index.
A
Buy 6/23/2014Downgrade
Pfizer Inc. (PFE) was downgraded to A- from A on 6/23/2014 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 49.27% from $5.79B to $2.94B, total revenue declined 16.26% from $13.56B to $11.35B, and earnings per share declined from $0.3931 to $0.3613.
A
Buy 3/28/2014Upgraded
Pfizer Inc. (PFE) was upgraded to A from A- on 3/28/2014 due to a major increase in the valuation index, total return index and volatility index.
Weiss Ratings